Optogenetics is moving from a powerful laboratory research technique toward potential medical applications, including experimental treatments for blindness. The technology gained fresh global attention after the 2026 Nobel Prize in Physiology or Medicine recognised scientists Karl Deisseroth, Peter Hegemann and Georg Nagel for discoveries that enabled researchers to control nerve cells using light.
Optogenetics combines genetic engineering with light-sensitive proteins to selectively activate or inhibit specific nerve cells. This allows scientists to study how individual groups of neurons influence functions such as movement, hunger, pain, itch and behaviour.
The technique traces its roots to research on single-celled algae, where Hegemann and Nagel identified channelrhodopsin, a light-sensitive protein. Deisseroth later adapted the approach to nerve cells, demonstrating that neural activity could be precisely controlled with light.
From Research Tool to Experimental Treatment
One of the most advanced medical applications of optogenetics is retinal disease. Conditions such as retinitis pigmentosa can destroy photoreceptor cells and eventually cause severe vision loss or blindness.
Instead of correcting the specific genetic mutation responsible for retinal degeneration, optogenetic therapy attempts to make surviving retinal cells sensitive to light by introducing genes that produce light-sensitive proteins.
Experimental therapies including MCO-010 have been tested in people with advanced retinitis pigmentosa. Clinical studies have reported improvements in visual acuity, while longer-term follow-up continues to examine safety and durability. Another experimental treatment, AGN-151597, is being evaluated in an early-stage human trial.
However, these therapies remain investigational and have not received regulatory approval as established treatments.
India Is Also Advancing Optogenetics Research
Indian researchers are using optogenetics to investigate neural circuits linked to pain, itch, stress, feeding and behaviour. At the Indian Institute of Science (IISc), researchers have used genetic and optical techniques in mice to examine how specific brain circuits influence pain and itch.
India has also been involved in clinical research on optogenetic treatment for blindness. An early-stage MCO-010 study for advanced retinitis pigmentosa was conducted at the JPM Rotary Club of Cuttack Eye Hospital and Research Institute in Odisha.
Researchers at institutions including IISER Mohali, IISER Pune and CHINTA, Kolkata, are also exploring applications of optogenetics and neural circuit research.
Major Challenges Remain
The promise of optogenetics comes from its precision, but translating laboratory findings into widely available treatments remains difficult. Scientists must safely deliver genetic material to the correct cells, control those cells accurately and establish long-term safety.
For retinal conditions, treatment may be comparatively more accessible because the eye can be reached directly. Applying similar approaches to the brain presents additional challenges, including delivering light to deeper tissue, modifying neurons safely and understanding the long-term effects of altering neural circuits.
For now, optogenetics remains an emerging field, but its transition from neuroscience laboratories toward clinical research could open new possibilities for treating conditions that have traditionally been difficult to address.
Relevant Link: Indian Institute of Science Official Website
Conversation
Be kind and stay on topic. Comments are moderated; abuse, spam and personal attacks are removed. Report a problem